Vemurafenib for BRAFV600E-positive Metastatic Papillary Thyroid Cancer – Authors' Response
The Lancet Oncology - United Kingdom
doi 10.1016/s1470-2045(16)30520-4
Full Text
Open PDFAbstract
Available in full text
Categories
Date
November 1, 2016
Authors
Publisher
Elsevier BV